CRNX vs PHAT
CRNX: Crinetics Pharmaceuticals is a clinical-stage biotechnology company developing small molecule precision medicines for rare endocrine diseases and related tumors. PHAT: Phathom Pharmaceuticals is a biopharmaceutical company specializing in the development and commercialization of innovative treatments for gastrointestinal diseases, anchored by its potassium-competitive acid blocker platform.
Side-by-side fundamentals
| Metric | CRNX | PHAT | Edge |
|---|---|---|---|
| Price as of 2026-07-31 close | $83.52 | $8.75 | |
| Market cap as of 2026-08-03 | $8.8B | $708M | |
| PEG as of 2026-08-03 | -0.47 | n/a | |
| Net margin as of 2026-08-03 | -2747.2% | -76.8% | PHAT higher |
| Gross margin as of 2026-08-03 | +86.0% | +84.9% | CRNX higher |
| Operating margin as of 2026-08-03 | -3020.3% | -47.5% | PHAT higher |
| ROE as of 2026-08-03 | -44.0% | -232.8% | CRNX higher |
| ROA as of 2026-08-03 | -39.6% | -59.7% | CRNX higher |
| Debt / equity as of 2026-08-03 | 0.00 | 12.38 | CRNX lower |
| Revenue growth (YoY) as of 2026-08-03 | +2277.5% | +150.3% | CRNX higher |
| Beta as of 2026-08-03 | 1.10 | 1.11 | |
| 1-year return as of 2026-07-31 close | +192.1% | +2.5% | CRNX higher |
Fundamentals: market data, as of 2026-08-03. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-31.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.